Principles for development of similar biologics (biosimilars) MCQs With Answer

Introduction: Principles for development of similar biologics (biosimilars) MCQs With Answer

This blog provides a focused set of multiple-choice questions tailored for M.Pharm students studying regulatory aspects of biologics. It covers the scientific, analytical and regulatory principles central to development of similar biologics (biosimilars), including reference product selection, critical quality attributes, analytical comparability, clinical and non-clinical strategies, immunogenicity assessment, extrapolation of indications, interchangeability, post‑approval pharmacovigilance and manufacturing changes. The questions are designed to reinforce deep understanding of both conceptual and practical considerations used by regulators (WHO/EMA/FDA) and industry during biosimilar development, helping students prepare for exams and real‑world regulatory decision-making.

Q1. What is the most appropriate regulatory definition of a biosimilar?

• A small molecule generic identical to its reference drug
• A biological product that is identical in every way to the reference product
• A biological product highly similar to a licensed reference biologic with no clinically meaningful differences in safety, purity, and potency
• An unrelated biological product used for the same therapeutic indication

Correct Answer: A biological product highly similar to a licensed reference biologic with no clinically meaningful differences in safety, purity, and potency

Q2. What is the primary objective of comparative analytical characterization in biosimilar development?

• To prove the biosimilar is manufactured using the same cell line as the reference
• To demonstrate similarity in critical quality attributes that may impact clinical performance
• To replace clinical trials entirely
• To develop an identical manufacturing process to the innovator

Correct Answer: To demonstrate similarity in critical quality attributes that may impact clinical performance

Q3. Which of the following is least likely to be considered a critical quality attribute (CQA) for a monoclonal antibody biosimilar?

• Glycosylation profile
• Aggregate content
• Host cell protein residues
• Hardness of a tablet

Correct Answer: Hardness of a tablet

Q4. Why is selection of the appropriate reference product crucial in biosimilar development?

• Because the biosimilar must have the same brand name
• Because analytical and clinical comparability studies are performed against that reference to establish similarity
• Because the reference product determines the manufacturing cell bank
• Because the reference product’s patent life must be identical

Correct Answer: Because analytical and clinical comparability studies are performed against that reference to establish similarity

Q5. Under what conditions can a biosimilar sponsor seek extrapolation of indications?

• When marketing is cheaper in the extrapolated indication
• When scientific justification shows the mechanism of action, PK/PD, and safety profile are similar across indications
• When the reference product has a longer market history in that indication
• When no clinical trials are conducted at all

Correct Answer: When scientific justification shows the mechanism of action, PK/PD, and safety profile are similar across indications

Q6. Which statement best describes the role of immunogenicity assessment in biosimilar development?

• Immunogenicity testing is only required for innovator biologics
• Immunogenicity assessment is required both during development and post‑marketing for biosimilars
• Immunogenicity is not relevant for proteins produced in mammalian cells
• Only an antibody titer test is necessary without functional assessment

Correct Answer: Immunogenicity assessment is required both during development and post‑marketing for biosimilars

Q7. Which analytical techniques are commonly used to establish structural and functional similarity between a biosimilar and its reference?

• UV‑visible spectrophotometry only
• Mass spectrometry, peptide mapping, glycan analysis and orthogonal bioassays
• Only bacterial endotoxin testing
• Simple pH and osmolality measurements only

Correct Answer: Mass spectrometry, peptide mapping, glycan analysis and orthogonal bioassays

Q8. What is the typical role of non‑clinical (animal) studies in a modern biosimilar development program?

• Extensive repeat‑dose toxicology studies are always required
• Non‑clinical studies are often limited and focused on in‑vitro and targeted in‑vivo testing only if analytical differences raise concerns
• Non‑clinical studies can replace clinical trials entirely
• Animal studies are unnecessary if the product is produced in bacteria

Correct Answer: Non‑clinical studies are often limited and focused on in‑vitro and targeted in‑vivo testing only if analytical differences raise concerns

Q9. What is the primary purpose of comparative clinical trials for biosimilars?

• To develop a new dosing regimen superior to the reference
• To confirm there are no clinically meaningful differences in safety and efficacy versus the reference product
• To generate proprietary intellectual property
• To show superiority in all clinical endpoints

Correct Answer: To confirm there are no clinically meaningful differences in safety and efficacy versus the reference product

Q10. How should equivalence margins for a biosimilar clinical efficacy study be selected?

• Using arbitrarily chosen statistical values
• Based on previous superiority trials of the reference product
• Pre‑specified and clinically justified taking into account historical reference data and clinical relevance
• They are not necessary; non‑inferiority is always acceptable

Correct Answer: Pre‑specified and clinically justified taking into account historical reference data and clinical relevance

Q11. In the US regulatory framework, what does an ‘interchangeable’ designation imply?

• The biosimilar is cheaper than the reference product
• The product can be substituted for the reference at the pharmacy without prescriber intervention under state law
• The biosimilar has fewer side effects than the reference
• The biosimilar uses identical manufacturing equipment as the reference

Correct Answer: The product can be substituted for the reference at the pharmacy without prescriber intervention under state law

Q12. Which naming approach has been adopted by FDA to aid pharmacovigilance for biologics?

• Using only the INN with no suffix or prefix
• Assigning a nonproprietary name with a unique four‑letter suffix to distinguish products
• Using the brand name as the nonproprietary name
• Removing all identifiers to protect proprietary information

Correct Answer: Assigning a nonproprietary name with a unique four‑letter suffix to distinguish products

Q13. Which element is essential in a post‑approval risk management plan for a biosimilar?

• Plans to discontinue all pharmacovigilance within one year
• Active monitoring for immunogenicity, traceability, and adverse event reporting
• Only passive surveillance without traceability measures
• Limited labeling to avoid clinical use

Correct Answer: Active monitoring for immunogenicity, traceability, and adverse event reporting

Q14. Which guideline is commonly referenced for demonstrating comparability after manufacturing changes?

• ICH Q5E Comparability of Biotechnological/Biological Products
• ICH Q1A Stability only
• Guideline for small molecule impurities only
• No guideline is applicable

Correct Answer: ICH Q5E Comparability of Biotechnological/Biological Products

Q15. What is the purpose of using orthogonal analytical methods in biosimilarity assessment?

• To reduce the number of assays performed
• To provide independent confirmation of critical attributes using different principles
• To measure only purity and ignore function
• To ensure identical excipient profiles

Correct Answer: To provide independent confirmation of critical attributes using different principles

Q16. Why are glycosylation pattern differences between a biosimilar and reference product important?

• They only affect color and are clinically irrelevant
• They can influence biological activity, pharmacokinetics and immunogenicity
• They indicate contamination with non‑protein materials
• Glycosylation differences are not measurable

Correct Answer: They can influence biological activity, pharmacokinetics and immunogenicity

Q17. What is the regulatory stance on minor differences in clinically inactive components of a biosimilar?

• All differences are unacceptable and lead to rejection
• Minor differences are acceptable if they do not result in clinically meaningful differences in safety or efficacy
• Only active ingredient differences are acceptable
• Excipients must be identical by regulation

Correct Answer: Minor differences are acceptable if they do not result in clinically meaningful differences in safety or efficacy

Q18. When is a bridging study required during biosimilar development?

• When the biosimilar developer uses the same reference product lot throughout development
• When the reference product sourced in different regions may differ and a link between regional references must be established
• Bridging studies are never required
• Only if the biosimilar is administered orally

Correct Answer: When the reference product sourced in different regions may differ and a link between regional references must be established

Q19. What characteristic best describes a potency assay required for a biosimilar?

• It only measures protein concentration using UV absorbance
• It is a functional assay that measures biological activity relevant to mechanism of action
• It is optional and rarely used
• It only assesses endotoxin levels

Correct Answer: It is a functional assay that measures biological activity relevant to mechanism of action

Q20. Which stability testing approach is appropriate to establish shelf life for a biosimilar?

• Relying solely on the reference product’s expiry without data
• Performing product‑specific real‑time and accelerated stability studies to define expiry and storage conditions
• Using only short‑term freeze‑thaw cycles
• Assuming stability because the product is biologic

Correct Answer: Performing product‑specific real‑time and accelerated stability studies to define expiry and storage conditions

Download